Brain Cancer Clinical Trials in Cleveland

Showing 141-160 of 226 trials

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

GlioblastomaRecurrent GlioblastomaBrain Tumor

Kadmon Corporation, LLC40 participantsStarted Jun 2016

Tucson, Arizona, United States • Duarte, California, United States • San Francisco, California, United States +8 more locations

COMPLETEDPhase 2< 1 mile

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

Brain CancerBrain NeoplasmGlioma+8 more

DNAtrix, Inc.49 participantsStarted Oct 2016

Little Rock, Arkansas, United States • Los Angeles, California, United States • Chicago, Illinois, United States +12 more locations

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Brain Cancer Trials in Other Cities

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

ANG1005 in Patients With Recurrent High-Grade Glioma

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

UNITE Study: Understanding New Interventions With GBM ThErapy

Gliogene: Brain Tumor Linkage Study

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Other Conditions in Cleveland